<DOC>
	<DOCNO>NCT00942487</DOCNO>
	<brief_summary>Summary : - Study title : Effects Nebivolol subclinical leave ventricular dysfunction . A comparative study Metoprolol . ( ENESYS study ) - Study phase : 3 - Study design ( parallel , cross-over , etc . ) , randomisation blinding procedure , type control ( placebo active ) : randomise , parallel , active-controlled , open label - Study treatment ( ) /drug ( ) : Nebivolol versus Metoprolol - Patients : - characteristic : patient hypertension leave ventricular hypertrophy - plan total number : 50 - Study duration : - total enrolment period ( month ) : 18 - treatment period ( month ) : 6 - follow period ( month ) : 6 - Total study duration ( month ) : 24 - Number Centres : 1 - Country ( y ) : Romania ( RO )</brief_summary>
	<brief_title>Effects Nebivolol Subclinical Left Ventricular dySfunction : A Comparative Study Against Metoprolol</brief_title>
	<detailed_description>STUDY OBJECTIVES 1 . PRIMARY : - Longitudinal myocardial velocity rest ( assessed tissue Doppler echocardiography ) - Systolic functional reserve ( calculate absolute relative increase myocardial systolic velocity peak stress rest ) - Brain natriuretic peptide ( BNP , NT-pro BNP ) 6-months period treatment nebivolol versus metoprolol . An improvement 20 % myocardial resting velocity systolic functional reserve consider clinically relevant . The working hypothesis improvement subclinical leave ventricular dysfunction 6 month treatment go great patient receive nebivolol receive metoprolol . 2 . SECONDARY : - Global systolic function ( ejection fraction ) - Radial myocardial velocity - Right ventricular function - Global diastolic function - Left ventricular mass index</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>age 18 year old , men woman , hospitalized outpatient history primary arterial hypertension daytime ambulatory blood pressure &gt; 140 and/or &gt; 90 mm Hg leave ventricular hypertrophy : LVMI &gt; 125 g/m2 men , &gt; 110 g/m2 woman , Devereux formula , recommend ESHESC guideline ( 14 ) sinus rhythm consent , sign Informed Consent Severe arterial hypertension ( systolic blood pressure &gt; 180 mm Hg and/or diastolic blood pressure &gt; 110 mm Hg ) Any history coronary heart disease ( stable angina , acute coronary syndrome , myocardial infarction ) Any history cerebrovascular disease Renal impairment ( creatinine &gt; 1.5 mg % men , &gt; 1.4 mg % woman ) Left ventricular global systolic dysfunction ( EF &lt; 45 % ) More mild valvar ( mitral aortic ) regurgitation Hypertrophic cardiomyopathy Pericarditis Cor pulmonale Pregnancy lactate woman Any significant comorbidities Contraindication betablocker therapy Concomitant treatment betablockers Participation another investigational study last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>arterial hypertension</keyword>
</DOC>